EGFR and neoplasm: Considering that many multi-kinase inhibitors under development have AXL as one of their targets, further exploration of the pharmacologic inhibition of this pathway in pre-clinical models, including tumor cells lines with resistance to anti-EGFR drugs, should be pursued.